Compare · ABT vs ELAN
ABT vs ELAN
Side-by-side comparison of Abbott Laboratories (ABT) and Elanco Animal Health Incorporated (ELAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ELAN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 16.0x ELAN ($12.54B).
- ELAN has been more active in the news (14 items in the past 4 weeks vs 8 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 24 for ELAN).
- Company
- Abbott Laboratories
- Elanco Animal Health Incorporated
- Price
- $116.11-0.50%
- $25.09+2.76%
- Market cap
- $200.95B
- $12.54B
- 1M return
- +11.04%
- -
- 1Y return
- -11.76%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 8
- 14
- Recent ratings
- 25
- 24
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest ELAN
- SEC Form 4 filed by Officer Modi Rajeev A.
- SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M
- SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N
- Director Kurzius Lawrence Erik bought $935,920 worth of shares (40,000 units at $23.40), increasing direct ownership by 27% to 188,647 units (SEC Form 4)
- GC AND CORP SEC O'Neill Shiv bought $94,273 worth of shares (3,998 units at $23.58), increasing direct ownership by 5% to 87,832 units (SEC Form 4)
- Director Harrington Michael J bought $109,100 worth of shares (5,000 units at $21.82), increasing direct ownership by 4% to 131,451 units (SEC Form 4)
- SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N
- EVP and CFO Vanhimbergen Robert M bought $96,926 worth of shares (4,200 units at $23.08), increasing direct ownership by 3% to 137,516 units (SEC Form 4)
- SEC Form 4 filed by Officer Modi Rajeev A.
- Director Herendeen Paul bought $236,850 worth of shares (10,000 units at $23.68), increasing direct ownership by 10% to 111,687 units (SEC Form 4)